Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | PRMT5 | O14744 | 7/20 | 0.49 |
| ▸ | GCK | P35557 | 1/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | YAP1 | P46937 | 2/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18549925 | 0.92 | PRMT5 (0.49) | MAPTPRMT5GCKMAPK1YAP1 | |
| SCHEMBL18549983 | 0.91 | MAPT (0.52) | MAPTPRMT5GCKGPR119S1PR5 | |
| SCHEMBL18563793 | 0.91 | MAPT (0.56) | MAPTPDE10AMAPK1GPR119 | |
| SCHEMBL18550139 | 0.90 | MAPT (0.49) | MAPTGCK | |
| SCHEMBL28745182 | 0.89 | S1PR5 (0.46) | S1PR5 | |
| SCHEMBL30785603 | 0.88 | MAPT (0.62) | MAPTPDE10AMAPK1 | |
| SCHEMBL6294666 | 0.88 | MAPT (0.62) | MAPTPDE10AMAPK1 | |
| SCHEMBL18563783 | 0.87 | MAPT (0.53) | MAPTPDE10AMAPK1GPR119 | |
| SCHEMBL18550053 | 0.87 | MAPT (0.51) | MAPTGCKPDE10AMAPK1GPR119 | |
| SCHEMBL18549875 | 0.86 | PRMT5 (0.51) | MAPTPRMT5GCKMAPK1YAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10556907-B2 | Fused heterocyclic compounds as S1P modulators | AbbVie Deutschland GmbH & Co. KG (DE) | 2020-02-11 | — | — | US | disclosed |
| US-20170057966-A1 | FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-03-02 | — | — | US | disclosed |
| US-20170057966-A1 | FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170057966-A1 | FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS | S1PR1, S1PR2, S1PR3 | MAPT 3696/4885PRMT5 2839/4885GCK 1705/4885 |
| US-10556907-B2 | Fused heterocyclic compounds as S1P modulators | S1PR1, S1PR2, S1PR3 | MAPT 3696/4885PRMT5 2839/4885GCK 1705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.